Imatinib and gefitinib have become first-line drugs due to their outstanding clinical efficacy in patients with BCR-ABL–positive CML [10,11,28,29]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.